子宮内膜症治療薬の世界市場2021年-2025年

◆英語タイトル:Global Endometriosis Drugs Market 2021-2025
◆商品コード:IRTNTR70538
◆発行会社(リサーチ会社):Technavio
◆発行日:2021年5月12日
◆ページ数:約120
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他地域
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

テクナビオ社は世界の子宮内膜症治療薬市場規模が、2021年~2025年まで年平均3%成長し、332.72百万ドルに達すると予測しています。本調査レポートでは、世界の子宮内膜症治療薬市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、製品別(ホルモン療法、鎮痛薬)分析、顧客状況、地域別状況、推進要因、企業状況、企業分析など、以下の構成でまとめております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・世界の子宮内膜症治療薬市場規模:製品別(ホルモン療法、鎮痛薬)
・顧客状況
・地域別状況
・推進要因
・企業状況
・企業分析
【レポートの概要】

Global Endometriosis Drugs Market 2021-2025
Technavio has been monitoring the endometriosis drugs market and it is poised to grow by USD 332.72 million during 2021-2025, progressing at a CAGR of over 3% during the forecast period. Our report on the endometriosis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by recent approvals of advanced diagnostics and it is anticipated to boost the growth of the market as well.

The endometriosis drugs market analysis includes the product segment and geographic landscape.

Technavio’s endometriosis drugs market is segmented as below:
By Product
• Hormone therapy
• Analgesics

By Geographic
• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the strategic alliances as one of the prime reasons driving the endometriosis drugs market growth during the next few years. Also, strategic alliances will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on endometriosis drugs market covers the following areas:
• Endometriosis drugs market sizing
• Endometriosis drugs market forecast
• Endometriosis drugs market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading endometriosis drugs market vendors that include AbbVie Inc., AstraZeneca Plc, Bayer AG, Debiopharm International SA, Gedeon Richter Plc, Mayne Pharma Group Ltd., Merck and Co. Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the endometriosis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/endometriosis-drugs-market-size-industry-analysis
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

【レポートの目次】

• Executive Summary
o Market overview
• Market Landscape
o Market ecosystem
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020-2025
• Five Forces Analysis
o Five forces summary
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Hormone therapy – Market size and forecast 2020-2025
o Analgesics – Market size and forecast 2020-2025
o Market opportunity by Product
• Customer Landscape
o Overview
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o Rest of World (ROW) – Market size and forecast 2020-2025
o US – Market size and forecast 2020-2025
o UK – Market size and forecast 2020-2025
o Japan – Market size and forecast 2020-2025
o Germany – Market size and forecast 2020-2025
o Canada – Market size and forecast 2020-2025
o Market opportunity by geography
• Drivers, Challenges, and Trends
o Market drivers
o Market challenges
o Impact of drivers and challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o AbbVie Inc.
o AstraZeneca Plc
o Bayer AG
o Debiopharm International SA
o Gedeon Richter Plc
o Mayne Pharma Group Ltd.
o Merck and Co. Inc.
o Pfizer Inc.
o Takeda Pharmaceutical Co. Ltd.
o Teva Pharmaceutical Industries Ltd.
• Appendix
o Scope of the report
o Inclusions and exclusions checklist
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key finding 1
• 2: Key finding 1
• 3: Key finding 2
• 4: Key finding 3
• 5: Key finding 4
• 6: Key finding 5
• 7: Key finding 5
• 8: Key finding 6
• 9: Market characteristics
• 10: Parent market
• 11: Offerings of vendors included in the market definition
• 12: Market segments
• 13: Global – Market size and forecast 2020-2025 ($ million)
• 14: Global – Market size and forecast 2020-2025 ($ million)
• 15: Global Market: Year-over-year growth 2020-2025 (%)
• 16: Global Market: Year-over-year growth 2020-2025 (%)
• 17: Five forces analysis 2020 and 2025
• 18: Bargaining power of buyers
• 19: Bargaining power of suppliers
• 20: Threat of new entrants
• 21: Threat of substitutes
• 22: Threat of rivalry
• 23: Market condition – Five forces 2020 and 2025
• 24: Product – Market share 2020-2025 (%)
• 25: Product – Market share 2020-2025 (%)
• 26: Comparison by Product
• 27: Comparison by Product
• 28: Hormone therapy – Market size and forecast 2020-2025 ($ million)
• 29: Hormone therapy – Market size and forecast 2020-2025 ($ million)
• 30: Hormone therapy – Year-over-year growth 2020-2025 (%)
• 31: Hormone therapy – Year-over-year growth 2020-2025 (%)
• 32: Analgesics – Market size and forecast 2020-2025 ($ million)
• 33: Analgesics – Market size and forecast 2020-2025 ($ million)
• 34: Analgesics – Year-over-year growth 2020-2025 (%)
• 35: Analgesics – Year-over-year growth 2020-2025 (%)
• 36: Market opportunity by Product ($ million)
• 37: Customer landscape
• 38: Market share by geography 2020-2025 (%)
• 39: Market share by geography 2020-2025 (%)
• 40: Geographic comparison
• 41: Geographic comparison
• 42: North America – Market size and forecast 2020-2025 ($ million)
• 43: North America – Market size and forecast 2020-2025 ($ million)
• 44: North America – Year-over-year growth 2020-2025 (%)
• 45: North America – Year-over-year growth 2020-2025 (%)
• 46: Europe – Market size and forecast 2020-2025 ($ million)
• 47: Europe – Market size and forecast 2020-2025 ($ million)
• 48: Europe – Year-over-year growth 2020-2025 (%)
• 49: Europe – Year-over-year growth 2020-2025 (%)
• 50: Asia – Market size and forecast 2020-2025 ($ million)
• 51: Asia – Market size and forecast 2020-2025 ($ million)
• 52: Asia – Year-over-year growth 2020-2025 (%)
• 53: Asia – Year-over-year growth 2020-2025 (%)
• 54: Rest of World (ROW) – Market size and forecast 2020-2025 ($ million)
• 55: Rest of World (ROW) – Market size and forecast 2020-2025 ($ million)
• 56: Rest of World (ROW) – Year-over-year growth 2020-2025 (%)
• 57: Rest of World (ROW) – Year-over-year growth 2020-2025 (%)
• 58: US – Market size and forecast 2020-2025 ($ million)
• 59: US – Market size and forecast 2020-2025 ($ million)
• 60: US – Year-over-year growth 2020-2025 (%)
• 61: UK – Market size and forecast 2020-2025 ($ million)
• 62: UK – Market size and forecast 2020-2025 ($ million)
• 63: UK – Year-over-year growth 2020-2025 (%)
• 64: Japan – Market size and forecast 2020-2025 ($ million)
• 65: Japan – Market size and forecast 2020-2025 ($ million)
• 66: Japan – Year-over-year growth 2020-2025 (%)
• 67: Germany – Market size and forecast 2020-2025 ($ million)
• 68: Germany – Market size and forecast 2020-2025 ($ million)
• 69: Germany – Year-over-year growth 2020-2025 (%)
• 70: Canada – Market size and forecast 2020-2025 ($ million)
• 71: Canada – Market size and forecast 2020-2025 ($ million)
• 72: Canada – Year-over-year growth 2020-2025 (%)
• 73: Market opportunity by geography
• 74: Impact of drivers and challenges
• 75: Vendor landscape
• 76: Industry risks
• 77: Landscape disruption
• 78: Vendors covered
• 79: Market positioning of vendors
• 80: AbbVie Inc. – Overview
• 81: AbbVie Inc. – Product / Service
• 82: AbbVie Inc. – Key news
• 83: AbbVie Inc. – Key offerings
• 84: AstraZeneca Plc – Overview
• 85: AstraZeneca Plc – Product / Service
• 86: AstraZeneca Plc – Key news
• 87: AstraZeneca Plc – Key offerings
• 88: Bayer AG – Overview
• 89: Bayer AG – Business segments
• 90: Bayer AG – Key news
• 91: Bayer AG – Key offerings
• 92: Bayer AG – Segment focus
• 93: Debiopharm International SA – Overview
• 94: Debiopharm International SA – Product / Service
• 95: Debiopharm International SA – Key news
• 96: Debiopharm International SA – Key offerings
• 97: Gedeon Richter Plc – Overview
• 98: Gedeon Richter Plc – Business segments
• 99: Gedeon Richter Plc – Key news
• 100: Gedeon Richter Plc – Key offerings
• 101: Gedeon Richter Plc – Segment focus
• 102: Mayne Pharma Group Ltd. – Overview
• 103: Mayne Pharma Group Ltd. – Business segments
• 104: Mayne Pharma Group Ltd. – Key news
• 105: Mayne Pharma Group Ltd. – Key offerings
• 106: Mayne Pharma Group Ltd. – Segment focus
• 107: Merck and Co. Inc. – Overview
• 108: Merck and Co. Inc. – Business segments
• 109: Merck and Co. Inc. – Key news
• 110: Merck and Co. Inc. – Key offerings
• 111: Merck and Co. Inc. – Segment focus
• 112: Pfizer Inc. – Overview
• 113: Pfizer Inc. – Business segments
• 114: Pfizer Inc. – Key news
• 115: Pfizer Inc. – Key offerings
• 116: Pfizer Inc. – Segment focus
• 117: Takeda Pharmaceutical Co. Ltd. – Overview
• 118: Takeda Pharmaceutical Co. Ltd. – Product / Service
• 119: Takeda Pharmaceutical Co. Ltd. – Key news
• 120: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 121: Teva Pharmaceutical Industries Ltd. – Overview
• 122: Teva Pharmaceutical Industries Ltd. – Business segments
• 123: Teva Pharmaceutical Industries Ltd. – Key news
• 124: Teva Pharmaceutical Industries Ltd. – Key offerings
• 125: Teva Pharmaceutical Industries Ltd. – Segment focus
• 126: Inclusions checklist
• 127: Exclusions checklist
• 128: Currency conversion rates for US$
• 129: Research methodology
• 130: Validation techniques employed for market sizing
• 131: Information sources
• 132: List of abbreviations



【掲載企業】

AbbVie Inc., AstraZeneca Plc, Bayer AG, Debiopharm International SA, Gedeon Richter Plc, Mayne Pharma Group Ltd., Merck and Co. Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[子宮内膜症治療薬の世界市場2021年-2025年]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆